The "Aptamers Market - Technology Trend Analysis By Applications - Therapeutics, Diagnostics, Biosensors, Drug Discovery, Biomarker Discovery, Research Applications with Market Landscape Analysis - Global Forecasts to 2018 " analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.
Browse 14 market data tables with 29 figures spread through 171 Slides and in-depth TOC of "Aptamers Market - Technology Trend Analysis By Applications - Therapeutics, Diagnostics, Biosensors, Drug Discovery, Biomarker Discovery, Research Applications with Market Landscape Analysis - Global Forecasts to 2018".
http://www.marketsandmarkets.com/Market-Reports/aptamers-technology-market-1167.html
Early buyers will receive 10% customization on reports.
This report studies the global aptamers market, with forecast to 2018.
The global healthcare industry is witnessing a paradigm shift, skewed towards point-of-care diagnostics, cost-effective treatment modalities, and personalized medicine, which not only offers efficient early diagnosis, but also treats serious illnesses in order to reduce the cost and disease burden. Aptamers is one such technology with the potential to revolutionize medical diagnostics and therapeutics in healthcare.
This market research report evaluates the global market of aptamers by geography, applications, and aptamer type. Further, the applications market is divided into six segments, namely, therapeutics, diagnostics, biosensors, drug discovery, biomarker discovery, and research applications. Of the above mentioned application segments, research applications is the largest revenue segment; however, biomarker discovery and diagnostics will be the fastest-growing segment.
The global aptamers market was valued at $200 million in the year 2012. At the end of 2013, the market is expected to be $287 million and is poised to reach approximately $2.1 billion by 2018, growing at a CAGR of 49.24% from 2013 to 2018.
The biomarker discovery, drug discovery and diagnostics segments offer vast opportunities for key players in this market. The launch of the first aptamer drug, Macugen, and the first diagnostic test for testing mycotoxins in grains has acknowledged the potential of aptamers in therapeutics and diagnostics. This scenario is expected to further revolutionize the industry towards massive growth in the next 5 to 10 years.
The global market for aptamers is expected to grow, backed by technological advancements with respect to selection processes and synthesis. The market will experience continuous improvements in aptamer synthesis and its applicability in drug discovery and routine research. The market is witnessing a trend toward development of personalized medicine and point-of-care diagnostic tests. Additionally, the demand for safe and cost-effective drugs for treatment of cancer (which can be fulfilled by aptamer therapeutics), will remarkably fuel market growth. North America is the largest hub for aptamers market, accounting for the largest share, followed by Europe and Asia. North America and Europe are expected to
grow at a steady pace. However, the Asia-Pacific market, particularly India and China, is expected to witness a boost in demand and is poised to register maximum growth over the next five years, owing to the increased purchasing power of patients.
The key players in the aptamers market are AM Biotechnologies, LLC (U.S.), Aptagen, LLC (U.S.), Aptamer Sciences Inc. (South Korea), Aptamer Solutions Ltd (U.K.), Base Pair Biotechnologies (U.S.), Bioapter S.L. (Spain), Integrated Biotechnologies, Inc. (U.S.), NOXXON Pharma AG (Germany), OTC Biotech (U.S.), Regado Biosciences, Inc. (U.S.), Somalogic, Inc. (U.S.), and TriLink BioTechnologies, Inc. (U.S.).